All right, okay. We'll get started here. I'm Eric Joseph, Senior Biotech Analyst with JPMorgan. And our next presenting company is Novavax. Presenting on behalf of the company is CEO, John Jacobs.

Novavax (NVAX) finally passed all four necessary steps for its COVID-19 vaccine to be available for adults in the U.S. next week, with the final green light coming from the CDC. 3.2 million doses ...

The vaccine maker's shares plunged Wednesday as 2023 results and its 2024 revenue forecast disappointed investors. Novavax to pay millions in settlement with vaccine nonprofit Emergent BioSolutions ...

AKIKO FUJITA: As COVID hospitalizations surge with the rise of the Omicron variant, the race is heating up to get vaccines distributed across the globe. Novavax is the latest to file for emergency use ...

Gaithersburg, Maryland-based COVID-19 vaccine maker Novavax, which announced a restructuring this summer that included cutting its workforce by 25%, saw its third quarter revenue tumble and it plans ...

Shares for Novavax swelled by more than 130% Friday morning, after the biotech firm announced a $1.4 billion deal with Sanofi to commercialize its Covid vaccine and develop a new combination shot for ...

Novavax Inc NVAX reported Q3 revenue of $187 million, compared to $735 million in the same period in 2022, beating the consensus of $158.54 million. "We've really optimized that U.S. grant opportunity ...

Stream Connecticut News for free, 24/7, wherever you are. Shares of Novavax closed nearly 100% higher on Friday from their previous day close of $4.47 apiece. The licensing agreement will allow ...

Pharmaceutical giant Novavax on Monday announced that the U.S. Food and Drug Administration (FDA) approved its COVID-19 vaccine, Nuvaxovid. Novavax’s shares traded nearly 20% in pre-market trading at ...

Novavax isn’t in a good financial position to be refunding money to customers, having gone through a cost-saving restructuring amid flagging sales of the Covid-19 vaccine that is its only ...

Novavax's stock almost doubled on Friday after it announced the licensing agreement with Sanofi. Novavax on Friday said the deal allows the company to remove its "going concern" warning, which it ...

Shares of Novavax closed nearly 50% higher on Monday as Wall Street cheered the company's new multibillion-dollar deal with French drugmaker Sanofi that sparked a dramatic turnaround for the ...